ClinicalTrials.gg
RecruitingNCT05940038Updated Oct 30, 2023

Retrospective Study of the Safety and Efficacy of PLLA for Skin Flaccidity in Labia Majora and/or Pubis Region

An observational study in Skin Laxity, sponsored by Galderma Brasil Ltda.. Recruiting at 1 site in Brazil. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-30.

Sponsored by Galderma Brasil Ltda. (part of Galderma Group AG) · Observational

From the registry’s dates

  • Primary completion was expected by Oct 2023, 3 years 1 month ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
10
Ages
18 Years and older
Sex
Female
01

Study summary

Phase IV, retrospective, single-center, clinical trial, chart review to evaluate the safety and efficacy of poly-L-l-lactic acid [PLLA-SCA, Sculptra®] in women who underwent at least one treatment for skin flaccidity of the labia majora and/or pubis region for safety evaluation and three treatment sessions for efficacy evaluation.

Read the detailed description

This is a phase IV, retrospective, single-center, clinical trial of medical record data collection to evaluate the safety and effectiveness in subjects who have undergone at least one application of poly-L-l-lactic acid (Sculptra®) for skin flaccidity treatment in the labia majora and/or pubis region. All medical charts of subjects treated for this condition at the clinic treated from Jan1st 2022 and on will be screened for inclusion. The reason for not including a subject will be documented.

During the study, the medical records of subjects who presented skin flaccidity of the labia majora and/or pubis region will be evaluated to anamnesis and physical examination and information will be obtained on demographic data, clinical history, previous treatment(s) in the study region, number of treatment sessions with Sculptra®, as well as data on product dilution, technique used, doses injected, and adverse events related to Sculptra® and/or the injection procedure. Clinical evaluations will also be performed through the information and photographic records obtained through the evaluation of the medical records of these subjects.

02

Conditions studied

  • Skin Laxity
03

In context

Lead sponsor

Galderma Brasil Ltda. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All medical records of female subjects who received at least one (1) application of Sculptra® for the treatment of skin flaccidity of the labia majora and/or pubis, from Jan1st 2022 and on, on the private practice of the investigators will be screened for inclusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects able to read, or follow reading, understand, and sign the Form and the Authorization Form for Imaging Usage approved by the REC/CONEP system;
  2. Subjects aged 18 years or older;
  3. Having received at least 1 (one) session of Sculptra® for labia majora and/or mons pubis skin flaccidity.
  4. Available clinical information and treatment data in the medical records.
  5. Having medical records that present suitable photographic records prior and after the Sculptra® injections that allow a skin condition assessment of labia majora and/or mons pubis.

Exclusion criteria

Exclusion Criteria:

  1. Having any clinical condition or laboratory disorder, recorded at the medical record, which may compromise trial participation according to the investigator assessment.
  2. Having any procedure performed on the labia majora and/or mons pubis skin within12 months prior to the first administration of PLLA (Sculptra®).
  3. Participation in another clinical trial in the 30 days previous the study start.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
10 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number of AEs

    Time frame: Since first application up to 12 months follow up.

  2. Number (%) of AEs related to the study product or injection procedure

    Time frame: Since first application up to 12 months follow up.

  3. Number of AEs related (%) to the study product by intensity (if available)

    Time frame: Since first application up to 12 months follow up.

  4. Number (%) of subjects having at least one AE

    Time frame: Since first application up to 12 months follow up.

  5. Number (%) of subjects having at least one AE related to the study product or injection procedure

    Time frame: Since first application up to 12 months follow up.

  6. Number (%) of subjects who died

    Time frame: Since first application up to 12 months follow up.

  7. Improvement of cutaneous flaccidity of the labia majora and/or pubis region

    Assessed by the percentage of total scores (n, %): hugely better, much better, or better according to Global Aesthetic Improvement Scale

    Time frame: Since third application up to 12 months follow up since first application.

  8. Improvement of global aesthetic aspect of the labia majora and/or pubis region

    Assessed by the percentage of total scores (n, %): hugely better, much better, or better according to Global Aesthetic Improvement Scale

    Time frame: Since third application up to 12 months follow up since first application.

Other outcomes

  1. Improvement of symptoms related to functional complaints of the labia majora and/or mons pubis region

    Assessed by the total percentage (n, %) of reported outcomes as hugely better, much better, or better

    Time frame: Since third application up to 12 months follow up since first application.

07

Study locations

1 of 1 sites recruiting
  • Clínica Hexsel de Dermatologia
    Porto Alegre, Rio Grande Do Sul 90550-141, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Oct 2023, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2023
First posted
Jul 11, 2023
StartActual
Aug 23, 2023
Primary completionEst.
Oct 2023
CompletionEst.
Nov 2023
Last update
Oct 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05940038
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Aug 23, 2023
Primary completion
Oct 2023 (estimated)
Completion
Nov 2023 (estimated)
Last update
Oct 30, 2023

Study contacts

Carolina Siega
Contact
carolina.siega@galderma.com
5551998900275
Cristhine Kamamoto
Contact
cristhine.kamamoto@galderma.com
5511933157523

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion